GLP-1 Resource Center

Why has my weight loss stopped on Ozempic?

Weight loss plateaus on GLP-1 medications are common, expected, and rarely explained to patients. A plateau does not mean the medication has stopped working.

Why plateaus happen

Weight loss slows for well-understood reasons that apply with or without medication. A smaller body needs fewer calories, so the deficit that produced early loss shrinks as weight falls. Appetite and intake often drift upward as the body adjusts to treatment. And in the major GLP-1 trials, weight loss levels off after roughly a year even with continued dosing. The plateau is the expected shape of the curve, not a malfunction.

Other contributing factors

Across GLP-1 trials the share of weight lost as lean mass depends on the medication: about 26 percent on tirzepatide, and up to 45 percent on semaglutide, with a class-wide average near 30 percent and reported figures ranging from 20 to 50 percent.* The tirzepatide figure comes from the SURMOUNT-1 DXA substudy (Look et al., Diabetes, Obesity and Metabolism, 2025, 255 enrolled and 160 analysed), and the class-wide picture from a 2026 systematic review and meta-analysis in the International Journal of Obesity covering seven studies and 821 patients. Two things are worth holding alongside those numbers. In SURMOUNT-1 the placebo group lost the same ratio, 25 percent against 26 percent, so this is weight loss behaving as weight loss rather than the medication doing something unusual. And fat-free mass measured by DXA includes water, glycogen and connective tissue, so it is not skeletal muscle alone. Lean tissue contributes to resting energy use, so researchers discuss it as one factor among several in how energy needs change. It is not the single cause of a plateau. Separately, lower micronutrient and electrolyte intake, covered on the what nutrients Ozempic depletes page, can reduce energy levels to the point where daily activity decreases. Poor sleep and GLP-1 fatigue can compound that, and sleep disruption makes consistency harder. None of these breaks a plateau on its own; together they shape how much energy you have to live actively.

What the evidence supports

Adequate protein intake and movement against resistance two to three times per week are the approaches with the most evidence behind them for holding onto lean mass during weight loss. Most guidelines suggest 1.0 to 1.2 g/kg of body weight per day during active weight loss, and a 2026 review recommends 1.2 to 1.5 g/kg. A meta-analysis across 24 trials found that higher protein intake during energy restriction preserved 0.43kg more fat-free mass than standard protein intake, an effect the authors describe as modest. Creatine has been studied extensively in general populations, with evidence during reduced intake still emerging; in a June 2026 JISSN meta-analysis of seven randomised trials in 608 postmenopausal women, benefits to lean mass and leg press strength appeared only at 5g or more daily combined with resistance movement, and not at lower doses or without the training. We do not claim supplements break plateaus. We formulate them to support what you eat and how you move while the medication does its work.* Attending to lean mass from the beginning of treatment leaves you stronger at every weight, which matters more than the number on the scale.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Always speak with your healthcare provider about medication side effects or medical concerns.